Diabetes drugs and cardiovascular event reduction: A paradigm shift

Abstract

This review article summarizes the recent cardiovascular outcome data for sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 analogues, which have been found to reduce cardiovascular events. We also detail the implications these new medications will have on clinical practice through a review of recent diabetes guidelines and cost-effectiveness data.